- Condition: Type 1 Diabetes
Intervention: Device: Pump suspension
Sponsors: In Home Closed Loop Study Group; In Home Closed Loop Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified May 2012 - Conditions: Type 2 Diabetes; Overweight; Obesity
Interventions: Behavioral: Weight Watchers modified program; Other: Standard Care group
Sponsors: Medical University of South Carolina; Medical University of South Carolina; Weight Watchers International
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Sedentary Lifestyle; Physical Activity; Pre-Diabetic
Interventions: Behavioral: Mobile phone based physical activity with intervention; Behavioral: Pedometer Only
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Lixisenatide (AVE0010); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec; Drug: insulin glargine
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Conditions: Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis
Interventions: Drug: RM-131; Drug: Placebo
Sponsors: Rhythm Pharmaceuticals, Inc.; Rhythm Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Diabetes; Heart Failure
Intervention: Drug: Metformin
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified April 2012 - Conditions: Diabetic Macular Edema.; Non-proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy
Interventions: Drug: dexamethasone intravitreal implant; Drug: intravitreal bevacizumab
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012 - Condition: Glycemic Control
Interventions: Drug: TAK-875; Drug: Sitagliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Centre (Europe) Ltd.
Recruiting - verified May 2012 - Conditions: Diabetes; Pregnancy
Interventions: Other: Dietary counseling, exercise and self blood glucose monitoring; Other: Minimum intervention control group
Sponsors: Stanford University; Stanford University; Santa Clara Valley Health & Hospital System
Recruiting - verified March 2012 - Condition: Diabetic Foot Ulcers
Interventions: Other: Tissue; Other: Control
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2012 - Condition: Diabetic Complications
Interventions: Device: Prontosan; Device: Saline
Sponsors: B. Braun Medical Inc.; B. Braun Medical Inc.
Recruiting - verified May 2012 - Conditions: Diabetes; Retinal Disorders
Intervention:
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Neuro Kinetics; Jules Stein Eye Institute; National Eye Institute (NEI)
Recruiting - verified March 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Diabetes Care Center; Diabetes Care Center; Medtronic
Recruiting - verified March 2012 - Condition: Prediabetes
Interventions: Dietary Supplement: Blood Sugar Take Care; Dietary Supplement: Placebo
Sponsors: NewChapter, Inc.; NewChapter, Inc.; Sprim Advanced Life Sciences
Not yet recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Technosphere Insulin Inhalation Powder; Drug: Rapid Acting Analog
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Condition: Diabetic Neuropathy, Painful
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Diabetic Neuropathy; Chemotherapy Induced Neuropathy; HIV Neuropathy; Trauma Induced Neuropathy
Intervention: Drug: Neuron012703 (Medical Food)
Sponsors: Targeted Medical Pharma; Targeted Medical Pharma
Not yet recruiting - verified February 2012 - Conditions: Diabetic Peripheral Neuropathy; Pain
Interventions: Drug: QUTENZA; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Device: Sham Injection; Drug: Rapid Acting insulin with pre-treatment of rHuPH20
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: PF-04937319 10 mg; Drug: PF-04937319 50 mg; Drug: PF-04937319 100 mg; Drug: Glimepiride
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Painful Diabetic Neuropathy
Interventions: Drug: SKL11197; Drug: Placebo
Sponsors: SK Life Science; SK Life Science
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: metformin; Drug: linagliptin; Drug: linagliptin medium dose; Drug: metformin placebo; Drug: metformin placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin degludec; Drug: insulin detemir; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Lixisenatide (AVE0010)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: CAT 1004; Drug: Placebo; Drug: CAT 1004; Drug: CAT 1004; Drug: CAT 1004; Drug: CAT 1004
Sponsors: Catabasis Pharmaceuticals; Catabasis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Gestational Diabetes; Obesity
Interventions: Dietary Supplement: Magnesium citrate; Dietary Supplement: Placebo; Behavioral: Dietary modification
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified January 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Conditions: Hypertension; Diabetes
Interventions: Drug: Placebo; Drug: Azilsartan medoxomil; Drug: Azilsartan medoxomil
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Type 1 Diabetes
Interventions: Device: Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature; Device: Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
Sponsors: Medtronic Diabetes; Medtronic Diabetes
Recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - New formulation of insulin glargine; Drug: HOE 901 - Insulin glargine
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: HOE 901 - Insulin glargine; Drug: HOE901 - Insulin glargine-new formulation
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: DS-5565 tablet; Drug: pregabalin capsule; Drug: Placebo
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified March 2012 - Conditions: Diabetes Mellitus; Type 1 Diabetes; Metabolic and Nutritional Disorders
Intervention: Device: TTR controller (Medtronic)
Sponsors: Stanford University; Stanford University; Medtronic
Recruiting - verified December 2011 - Condition: Gestational Diabetes
Intervention: Behavioral: Lifestyle Counseling
Sponsors: Kaiser Permanente; Kaiser Permanente
Recruiting - verified February 2012 - Conditions: Type 2 Diabetes Mellitus; Chronic Kidney Disease
Interventions: Drug: CTP-499; Drug: Placebo
Sponsors: Concert Pharmaceuticals; Concert Pharmaceuticals
Recruiting - verified March 2012 - Condition: Type 2 Diabetic Nephropathy
Interventions: Drug: PF-03882845; Drug: PF-03882845; Drug: PF-03882845; Drug: Spironolactone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Diabetes Mellitus; Type 2 Diabetes
Interventions: Drug: Sitagliptin; Drug: Metformin; Drug: Placebo to sitagliptin; Drug: Placebo to metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Intervention: Behavioral: Coronary Health Improvement Project Program
Sponsors: Kaiser Permanente; Kaiser Permanente
Not yet recruiting - verified November 2011 - Conditions: Acute Lymphoblastic Leukemia; Hyperglycemia; Insulin Resistance; Diabetes Mellitus
Intervention: Drug: Metformin
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Proliferative Diabetic Retinopathy
Interventions: Other: Prompt Panretinal Photocoagulation; Drug: 0.5-mg Ranibizumab; Other: Deferred panretinal photocoagulation
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); Genentech
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Conditions: Diabetes; Obesity
Interventions: Behavioral: Alive-PD; Behavioral: Usual Care
Sponsors: Berkeley Analytics, Inc.; Berkeley Analytics, Inc.
Not yet recruiting - verified November 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Atorvastatin; Other: Placebo to sitagliptin; Other: Placebo to atorvastatin; Drug: Metformin; Drug: Glimepiride; Drug: Placebo to glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Biological: albiglutide; Biological: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified January 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: GK1-399 (formerly TTP399); Drug: GK1-399 (formerly TTP399); Drug: GK1-399 (formerly TTP399); Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified January 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin; Drug: Sitagliptin / Metformin; Drug: Placebo to Metformin; Drug: Placebo to Sitagliptin / Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin Glargine; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Painful Diabetic Neuropathies
Interventions: Genetic: Low Dose: 16 mg VM202; Genetic: High Dose: 32 mg VM202; Genetic: Placebo (Normal Saline)
Sponsors: ViroMed Co., Ltd.; ViroMed Co., Ltd.; VM Biopharma
Not yet recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin glargine /lixisenatide fixed combination (HOE901/AVE0010); Drug: Insulin glargine (HOE901)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus
Intervention:
Sponsors: Medtronic Diabetes; Medtronic Diabetes
Recruiting - verified December 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Comparator: Placebo; Biological: Insulin Glargine; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Device: Sansum Closed-Loop Glucose Control Device
Sponsors: Sansum Diabetes Research Institute; Sansum Diabetes Research Institute; University of California, Santa Barbara
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PF-04991532; Drug: PF-04991532; Drug: PF-04991532; Drug: PF-0499132; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Diabetes
Intervention: Drug: Technosphere® Insulin Inhalation System
Sponsors: South Orange County Endocrinology; South Orange County Endocrinology
Not yet recruiting - verified October 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: TAK-875; Drug: TAK-875
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: ITCA 650; Other: ITCA placebo
Sponsors: Intarcia Therapeutics; Intarcia Therapeutics
Not yet recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: ITCA 650 60 mcg/day; Drug: glimepiride
Sponsors: Intarcia Therapeutics; Intarcia Therapeutics
Not yet recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: ITCA 650 60 mcg/day; Drug: sitagliptin
Sponsors: Intarcia Therapeutics; Intarcia Therapeutics
Not yet recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: ITCA 650; Drug: glimepiride
Sponsors: Intarcia Therapeutics; Intarcia Therapeutics
Not yet recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: ITCA 650 60 mcg/day; Drug: sitagliptin
Sponsors: Intarcia Therapeutics; Intarcia Therapeutics
Not yet recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: ITCA 650; Other: ITCA placebo
Sponsors: Intarcia Therapeutics; Intarcia Therapeutics
Not yet recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Diabetes Mellitus
Intervention: Drug: AMG 151
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Conditions: Gastroparesis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: 10mg TZP-102; Drug: 20mg TZP-102
Sponsors: Tranzyme, Inc.; Tranzyme, Inc.
Recruiting - verified April 2012 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Technosphere Insulin; Drug: Technosphere Inhalation Powder
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Condition: Diabetes Mellitus
Interventions: Drug: HM11260C; Drug: Placebo
Sponsors: Hanmi Pharmaceutical Company Limited; Hanmi Pharmaceutical Company Limited
Not yet recruiting - verified October 2011 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Technosphere Insulin with MedToneC Inhaler in combination with a basal insulin; Drug: Technosphere Insulin with Gen2C Inhaler in combination with a basal insulin; Drug: Insulin Aspart in combination with a basal insulin
Sponsors: Mannkind Corporation; Mannkind Corporation
Recruiting - verified May 2012 - Condition: Diabetic Foot Ulcer
Interventions: Device: SECONDARY dressing gauze and tape; Procedure: debridement, irrigation; Device: Dermagraft™; Device: Oasis™
Sponsors: VA Northern California Health Care System; VA Northern California Health Care System
Recruiting - verified October 2011 - Conditions: Choroidal Neovascularization; Diabetic Retinopathy; Diabetic Macular Edema
Interventions: Drug: PF-04523655 (Stratum I); Drug: PF-04523655 and ranibizumab; Drug: ranibizumab; Drug: PF-04523655 (Stratum II)
Sponsors: Quark Pharmaceuticals; Quark Pharmaceuticals
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: PF-04937319 - 3mg; Drug: PF-04937319 - 20mg; Drug: PF-04937319 - 50mg; Drug: PF-04937319 - 100mg; Drug: Sitagliptin - 100mg
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo matching with Saxagliptin; Drug: Metformin IR; Drug: Metformin XR; Drug: Saxagliptin; Drug: Saxagliptin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Glargine; Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Angina Pectoris; Coronary Artery Disease; Type 2 Diabetes Mellitus
Intervention: Drug: Ranolazine
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: linagliptin; Drug: BI 10773 linagliptin FDC; Drug: BI 10773 linagliptin FDC; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: linagliptin; Drug: linagliptin; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: BI 10773; Drug: BI 10773 high dose; Drug: BI 10773 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Lower Extremity Chronic Ulcers; Diabetes Mellitus
Interventions: Biological: Curexcell; Biological: Sham injection
Sponsors: Macrocure Ltd.; Macrocure Ltd.; Averion International Corporation
Recruiting - verified September 2011 - Conditions: Heart Failure; Diabetes Mellitus
Intervention: Procedure: 12-week supervised weight loss intervention
Sponsors: University of California, Irvine; University of California, Irvine; University of California, Los Angeles
Recruiting - verified August 2011 - Condition: Diabetes
Intervention: Other: Daily text messages
Sponsors: University of Southern California; University of Southern California
Recruiting - verified July 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: lisinopril; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetic Nephropathy; Chronic Kidney Disease
Interventions: Drug: Atrasentan; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Condition: Insulin Resistance
Intervention: Behavioral: Sleep restriction
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: Hypertension; Stage 2 Hypertension; Diabetes
Interventions: Drug: Valturna + amlodipine; Drug: valturna + placebo; Drug: Valturna + chlorthalidone
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2012 - Conditions: Cerebral Edema; Diabetic Ketoacidosis
Interventions: Other: Intravenous fluid; Other: intravenous fluid; Other: intravenous fluid; Other: Intravenous fluid
Sponsors: University of California, Davis; University of California, Davis; Children's Hospital of Philadelphia; Washington University School of Medicine; University of Utah; Children's Research Institute; Children's Hospital Boston; Columbia University; University of Colorado, Denver; Nationwide Children's Hospital; Children's Memorial Hospital; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified June 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Biological: albiglutide (GSK716155); Biological: albiglutide (GSK716155)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Type1 Diabetes
Intervention: Biological: Glargine
Sponsors: Wockhardt; Wockhardt
Recruiting - verified May 2011 - Conditions: Overweight; Obese; Obesity; Diabetic; Type 2 Diabetes
Interventions: Other: Higher Carbohydrate, Lower Fat Diet; Other: Lower carbohydrate, Higher fat diet; Other: Individualized Counseling
Sponsors: University of California, San Diego; University of California, San Diego; HealthPartners Research Foundation; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified February 2012 - Conditions: Gestational Diabetes; Obesity
Intervention: Behavioral: Lifestyle Counseling
Sponsors: Kaiser Permanente; Kaiser Permanente; Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified May 2012 - Conditions: Diabetes; Diabetic Retinopathy
Intervention: Behavioral: Diabetes Education
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Intervention: Device: V-Go™
Sponsors: Valeritas, Inc.; Valeritas, Inc.; Integrated Medical Development, LLC
Recruiting - verified April 2012 - Conditions: Diabetes; Pre-Diabetes
Intervention: Drug: water-soluble cinnamon extract (Cinnulin PF)
Sponsors: Mike O'Callaghan Federal Hospital; Mike O'Callaghan Federal Hospital
Not yet recruiting - verified April 2012 - Condition: Diabetic Peripheral Neuropathic Pain
Interventions: Drug: BMS-954561; Drug: Pregabalin; Drug: BMS-954561; Drug: Placebo matching BMS-954561; Drug: Placebo matching Pregabalin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Sitagliptin 100mg; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetic Foot Ulcers
Interventions: Device: Epiflo; Other: Moist Wound Therapy
Sponsors: Ogenix Corporation; Ogenix Corporation
Recruiting - verified December 2011 - Conditions: Fibromyalgia; Painful Diabetic Peripheral Neuropathy
Interventions: Other: prior authorization; Other: no prior authorization; Other: prior authorization; Other: no prior authorization
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Type 1 Diabetes
Intervention: Device: Control-to-Range Automated Insulin Management System
Sponsors: Juvenile Diabetes Research Foundation Artificial Pancreas Project Consortium; Juvenile Diabetes Research Foundation Artificial Pancreas Project Consortium
Recruiting - verified February 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Estradiol, medroxyprogesterone, hydrocortisone, growth hormone; Drug: Matching placebo
Sponsors: Sansum Diabetes Research Institute; Sansum Diabetes Research Institute
Not yet recruiting - verified July 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol for oral suspension placebo proxy; Drug: Welchol for oral suspension
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Gastroparesis
Interventions: Drug: GSK962040 (5 mg tablet); Drug: GSK962040 (25 mg tablet); Drug: GSK962040 (125 mg tablet); Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Cardiovascular Disease; Diabetes; Obesity; Aging
Intervention: Behavioral: Physical Activity and Diet Intervention via Alive2
Sponsors: Berkeley Analytics, Inc.; Berkeley Analytics, Inc.
Recruiting - verified June 2011 - Condition: Foot Ulcers, Diabetic
Intervention: Device: PriMatrix
Sponsors: TEI Biosciences Inc.; TEI Biosciences Inc.; Mayo Clinic; California School of Podiatric Medicine; New York College of Podiatric Medicine; Temple University
Recruiting - verified June 2011 - Conditions: Diabetes; Hypertension; Hyperlipidemia
Intervention: Behavioral: Health coaching by medical assistants in primary care
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Insulin lispro; Drug: Glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Biological: Ex vivo Expanded Human Autologous CD4+CD127lo/-CD25+ Polyclonal Regulatory T Cells
Sponsors: University of California, San Francisco; University of California, San Francisco; Juvenile Diabetes Research Foundation; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: liraglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo (Saxagliptin); Drug: Metformin IR; Drug: Placebo (Metformin); Drug: Metformin (Active Rescue)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Insulin; Drug: Insulin; Drug: Insulin LISPRO
Sponsors: Hompesch, Marcus, M.D.; Hompesch, Marcus, M.D.; Profil Institute for Clinical Research, Inc.
Not yet recruiting - verified June 2011 - Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Pioglitazone 15 mg; Drug: Pioglitazone 45 mg; Drug: Pioglitazone 30 mg; Drug: BI 1356 / Pioglitazone 15 mg FDC; Drug: BI 1356; Drug: BI 1356 / Pioglitazone 30 mg FDC; Drug: BI 1356 / Pioglitazone 45 mg FDC
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Blood draw
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetic Foot Ulcers
Interventions: Drug: Santyl; Other: White Petrolatum
Sponsors: Healthpoint; Healthpoint
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Anti-Thymocyte Globin plus pegylated GCSF; Drug: Placebo
Sponsors: University of Florida; University of Florida; The Helmsley Charitable Trust; Genzyme
Recruiting - verified February 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: DiaPep277; Drug: Placebo
Sponsors: Andromeda Biotech Ltd.; Andromeda Biotech Ltd.
Recruiting - verified September 2011 - Condition: Diabetes Mellitus
Interventions: Drug: BGP-15 100 mg QD; Drug: BGP-15 100 mg BID; Drug: Placebo BID; Drug: BGP-15 200 mg QD; Drug: BGP-15 200 mg BID; Drug: BGP-15 400 mg QD
Sponsors: N-Gene Research Laboratories, Inc.; N-Gene Research Laboratories, Inc.; Integrium; Msource Medical Development GmbH; Kinexum LLC; Thermo Fisher Scientific; Haupt Pharma Wülfing GmbH; BARC nv
Recruiting - verified June 2011 - Condition: Foot Ulcer, Diabetic
Interventions: Device: Integra® Dermal Regeneration Template; Other: Conventional Wound Therapy
Sponsors: Integra LifeSciences Corporation; Integra LifeSciences Corporation
Recruiting - verified August 2011 - Conditions: Diabetes; Obesity; Weight Gain
Intervention: Behavioral: Behavioral Weight Loss Program
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Conditions: Autoantibody Positive; Non-diabetic Relatives at Risk for Type 1 Diabetes; High Risk; Impaired Glucose Tolerance
Intervention: Drug: Teplizumab
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified February 2012 - Condition: Diabetic Gastroparesis
Intervention: Device: CGMS and insulin pump
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011 - Condition: Type 2 Diabetes
Interventions: Behavioral: Telephone support and behavior change; Other: Diabetes self-management education
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University
Recruiting - verified July 2011 - Conditions: Vitreous Hemorrhage; Proliferative Diabetic Retinopathy
Interventions: Drug: Ranibizumab; Behavioral: Saline
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI)
Recruiting - verified February 2012 - Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Diabetic Foot Ulcer
Interventions: Drug: HO/03/03 10µg; Drug: Placebo
Sponsors: HealOr; HealOr; Clinigene International Ltd; Cato Research
Recruiting - verified December 2011 - Condition: Diabetes
Interventions: Drug: Cyclo-Z; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified December 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Behavioral: DDR; Behavioral: Treadmill
Sponsors: Charles Drew University of Medicine and Science; Charles Drew University of Medicine and Science; American Diabetes Association
Recruiting - verified February 2012 - Condition: Diabetes, Gestational
Intervention: Device: The Seven Continuous Glucose Monitoring System
Sponsors: Stanford University; Stanford University; DexCom, Inc.
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Placebo
Sponsors: Merck; Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol; Drug: placebo tablets
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified January 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2011 - Conditions: Non-alcoholic Fatty Liver Disease; Diabetes
Interventions: Other: Dietary intervention (calorie restricted diet); Other: Dietary intervention (calorie restricted diet)
Sponsors: University of California, San Francisco; University of California, San Francisco; Touro University; American Diabetes Association
Recruiting - verified April 2012 - Condition: Lipodystrophy
Intervention: Drug: metreleptin
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Type 2 Diabetes
Interventions: Drug: placebo; Drug: exenatide; Drug: exenatide
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified August 2011 - Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Other: Paleolithic diet; Other: ADA ( American Diabetes Association) recommended diet
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Islet transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012 - Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011
 |
Join Clinical Trials in California for Diabetes |
